Our study investigated for the first time the serum levels of TGFβ1 in patients with and without bone metastasis and identified that both breast cancer patients with and without bone metastases had significantly lower levels compared to healthy age-matched controls. This evidence concerns the gene TGFB1 and breast carcinoma.